COMMUNIQUÉS West-GlobeNewswire

ALK – Financial calendar for the 2026 financial year
22/12/2025
2026 financial calendar for ALK ( ALKB:DC / OMX: ALK B ): 23 January 2026: Silent period 20 February 2026: Annual report 2025 16 March 2026 at 4.00 p.m.: Annual General Meeting Written requests to have specific business [...]
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
22/12/2025
- Halneuron ® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically [...]
PracticeLink Supports the Next Generation of Clinicians with Fall 2025 First Practice Fund Scholarships
22/12/2025
ST. LOUIS and HINTON, West Virginia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the leading online physician job board, announced today the [...]
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
22/12/2025
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1 -ALS Over 3 years, a subset of QALSODY-treated participants regained previously [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 novembre 2025
22/12/2025
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Le brevet pour le masitinib dans le traitement de la drépanocyose a été officiellement accordé aux Etats-Unis avec une protection jusqu'en 2040
22/12/2025
COMMUNIQUE DE PRESSE LE BREVET POUR LE MASITINIB DANS LE TRAITEMENT DE LA DRÉPANOCYOSE A ÉTÉ OFFICIELLEMENT ACCORDÉ AUX ÉTATS-UNIS AVEC UNE PROTECTION JUSQU'EN 2040 CETTE DÉCISION RENFORCE LE PORTEFEUILLE DE PROPRIÉTÉ [...]
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
22/12/2025
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY [...]
NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
22/12/2025
Ghent, Belgium, Dec. 22, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, [...]
EUROBIO SCIENTIFIC: REPLACEMENT OF A STATUTORY AUDITOR
22/12/2025
REPLACEMENT OF A STATUTORY AUDITOR Paris, December 22, 2025 – 6:00 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, announces the replacement of one [...]
EUROBIO SCIENTIFIC : REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES
22/12/2025
REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES Paris, le 22 décembre 2025 – 18h00 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2025
22/12/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - November 2025
22/12/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
22/12/2025
WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 [...]
Vivos Inc Summarizes Progress in its Animal Therapy Division
22/12/2025
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary [...]
BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™
22/12/2025
Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older BURLINGTON, Mass. and [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
22/12/2025
EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to [...]
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc . (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class Treatments for Chronic Kidney Disease
22/12/2025
Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify has developed oral, small molecules that can potentially reduce calcification by enhancing the [...]
Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus
22/12/2025
AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today opened access to [...]

Pages